Insider Transactions in Q1 2023 at Acadia Pharmaceuticals Inc (ACAD)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 24
2023
|
Brendan Teehan EVP, COO, HEAD OF COMMERCIAL |
SELL
Open market or private sale
|
Direct |
461
-8.15%
|
$8,298
$18.78 P/Share
|
|
Feb 24
2023
|
Austin D. Kim EVP,General Counsel, Secretary |
SELL
Open market or private sale
|
Direct |
803
-3.84%
|
$14,454
$18.78 P/Share
|
|
Feb 24
2023
|
Stephen Davis CEO |
SELL
Open market or private sale
|
Direct |
3,851
-4.03%
|
$69,318
$18.78 P/Share
|
|
Feb 24
2023
|
Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
577
-12.29%
|
$10,386
$18.78 P/Share
|
|
Feb 24
2023
|
James Kihara PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
350
-10.69%
|
$6,300
$18.78 P/Share
|
|
Feb 23
2023
|
Brendan Teehan EVP, COO, HEAD OF COMMERCIAL |
BUY
Exercise of conversion of derivative security
|
Direct |
1,107
+16.37%
|
-
|
|
Feb 23
2023
|
Austin D. Kim EVP,General Counsel, Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
2,214
+9.57%
|
-
|
|
Feb 23
2023
|
Stephen Davis CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,945
+10.27%
|
-
|
|
Feb 23
2023
|
Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,353
+22.37%
|
-
|
|
Feb 23
2023
|
James Kihara PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
840
+20.42%
|
-
|
|
Jan 12
2023
|
Laura Brege |
SELL
Open market or private sale
|
Direct |
12,500
-100.0%
|
$225,000
$18.25 P/Share
|
|
Jan 12
2023
|
Laura Brege |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+50.0%
|
$212,500
$17.01 P/Share
|
|
Jan 12
2023
|
Baker Bros. Advisors LP |
BUY
Exercise of conversion of derivative security
|
Indirect |
30,000
+0.23%
|
$150,000
$5.22 P/Share
|
|
Jan 09
2023
|
Brendan Teehan EVP, COO, HEAD OF COMMERCIAL |
SELL
Open market or private sale
|
Direct |
532
-10.47%
|
$9,044
$17.13 P/Share
|
|
Jan 09
2023
|
Stephen Davis CEO |
SELL
Open market or private sale
|
Direct |
3,904
-4.41%
|
$66,368
$17.13 P/Share
|
|
Jan 09
2023
|
Austin D. Kim EVP,General Counsel, Secretary |
SELL
Open market or private sale
|
Direct |
589
-3.05%
|
$10,013
$17.13 P/Share
|
|
Jan 06
2023
|
Brendan Teehan EVP, COO, HEAD OF COMMERCIAL |
BUY
Exercise of conversion of derivative security
|
Direct |
1,286
+20.2%
|
-
|
|
Jan 06
2023
|
Stephen Davis CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,528
+9.72%
|
-
|
|
Jan 06
2023
|
Austin D. Kim EVP,General Counsel, Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
1,633
+7.81%
|
-
|